Reports Q3 revenue $133.5M, consensus $122.6M. “Our record third quarter results reflect continued strong momentum in our business driven by successful global execution of our key strategic plans,” said Thomas Burns, CEO. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos Corp. Advances NEXAGON® Study for Eye Condition Treatment
- Glaukos Corp. Advances in Glaucoma Treatment with New Clinical Trial
- Glaukos Corp.’s iDose TR Study: A Potential Game-Changer in Ophthalmic Treatment
- Microsoft upgraded, Harley-Davidson downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Glaukos on ‘underappreciated’ growth opportunity